%0 Journal Article
%T Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study-IL PSO (Italian Landscape Psoriasis).
%A Valenti M
%A Gargiulo L
%A Ibba L
%A Malagoli P
%A Amoruso F
%A Balato A
%A Bardazzi F
%A Burlando M
%A Carrera CG
%A Dapavo P
%A Dini V
%A Gaiani FM
%A Girolomoni G
%A Guarneri C
%A Lasagni C
%A Loconsole F
%A Marzano AV
%A Maurelli M
%A Megna M
%A Orsini D
%A Travaglini M
%A Costanzo A
%A Narcisi A
%J Dermatol Ther (Heidelb)
%V 14
%N 6
%D 2024 Jun 15
%M 38748344
暂无%R 10.1007/s13555-024-01182-4
%X <B>BACKGROUND: </B>The introduction of biological therapies has revolutionized the treatment of moderate-to-severe plaque psoriasis. In particular, ixekizumab, an inhibitor of interleukin-17A, has shown great results in terms of efficacy and safety in both clinical trials and real-world experiences. However, there is a lack of long-term real-world data available for ixekizumab.<BR><B>METHODS: </B>We conducted a multicenter real-life study to evaluate the effectiveness and safety of ixekizumab in patients with moderate-to-severe plaque psoriasis. Psoriasis Area and Severity Index score (PASI) was collected at baseline and after 1, 2, 3, 4, and 5 years. The occurrence of any adverse events was recorded at each time point.<BR><B>RESULTS: </B>We enrolled 1096 patients treated with ixekizumab for at least 1 year. At week 52, the percentages of PASI 90 and PASI 100 were 85.04% and 69.07%, respectively. After 5 years of treatment with ixekizumab, out of 145 patients, a PASI 90 response was achieved by 86.90% of patients, while complete skin clearance was reached by 68.28% of patients. We did not observe any new significant safety findings throughout the study period.<BR><B>CONCLUSIONS: </B>This study supports the long-term effectiveness and safety of ixekizumab in a real-world setting.